

What is claimed is:

1. An IL-9 antibody comprising a variable heavy (VH) domain having an amino acid sequence of the VH domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
2. An IL-9 antibody comprising a variable light (VL) domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
3. The IL-9 antibody of claim 1 further comprising a VL domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
4. An IL-9 antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
5. The IL-9 antibody of claim 4, wherein the antibody comprises a VH CDR having an amino acid sequence of a VH CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
6. The IL-9 antibody of claim 4, wherein the antibody comprises a VL CDR having an amino acid sequence of a VL CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
7. The IL-9 antibody of claim 5 further comprising a VL CDR having the amino acid sequence of a VL CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
8. The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

9. The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
10. The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
11. The IL-9 antibody of claim 8, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
12. The IL-9 antibody of claim 8, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
13. The IL-9 antibody of claim 9, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
14. The IL-9 antibody of claim 11, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
15. The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
16. The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

17. The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
18. The IL-9 antibody of claim 15, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
19. The IL-9 antibody of claim 15, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
20. The IL-9 antibody of claim 16, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
21. The IL-9 antibody of claim 18, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
22. The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
23. The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
24. The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
25. The IL-9 antibody of claim 22, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-

- XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
26. The IL-9 antibody of claim 22, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 27. The IL-9 antibody of claim 23, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 28. The IL-9 antibody of claim 25, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 29. The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 30. The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 31. The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 32. The IL-9 antibody of claim 29, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
 33. The IL-9 antibody of claim 29, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-

- XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
34. The IL-9 antibody of claim 30, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
35. The IL-9 antibody of claim 32, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
36. The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
37. The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
38. The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
39. The IL-9 antibody of claim 36, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
40. The IL-9 antibody of claim 36, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
41. The IL-9 antibody of claim 37, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-

- XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
42. The IL-9 antibody of claim 39, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
43. The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
44. The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
45. The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
46. The IL-9 antibody of claim 43, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
47. The IL-9 antibody of claim 43, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
48. The IL-9 antibody of claim 44, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
49. The IL-9 antibody of claim 46, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-

XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

50. The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
51. The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
52. The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
53. The IL-9 antibody of claim 50, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
54. The IL-9 antibody of claim 50, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
55. The IL-9 antibody of claim 51, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
56. The IL-9 antibody of claim 53, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
57. The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

58. The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
59. The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
60. The IL-9 antibody of claim 57, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
61. The IL-9 antibody of claim 57, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
62. The IL-9 antibody of claim 58, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
63. The IL-9 antibody of claim 60, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
64. The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
65. The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

66. The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
67. The IL-9 antibody of claim 64, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
68. The IL-9 antibody of claim 64, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
69. The IL-9 antibody of claim 65, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
70. The IL-9 antibody of claim 67, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
71. The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
72. The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
73. The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
74. The IL-9 antibody of claim 71, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-

XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

83. The IL-9 antibody of claim 79, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
84. The IL-9 antibody of claim 81, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
85. The IL-9 antibody of claim 1, 2 or 3, wherein the antibody is a human or humanized antibody.
86. The IL-9 antibody of claim 1, 2 or 3, wherein the antibody is conjugated to a detectable substance or a therapeutic agent.
87. A pharmaceutical composition comprising the IL-9 antibody of claim 1, 2 or 3, and a pharmaceutically acceptable carrier.
88. A method for preventing, treating, managing and/or ameliorating a disease or disorder characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R, said method comprising administering to a subject in need thereof an prophylactically or therapeutically effective amount of the IL-9 antibody of claim 1, 2 or 3.
89. A method for preventing, treating, managing and/or ameliorating an inflammatory disorder, autoimmune disorder, a proliferative disorder or respiratory infection or one or more symptoms thereof, said comprising administering to a subject in need thereof a dosage of a prophylactically or therapeutically effective amount of the IL-9 antibody of claim 1, 2 or 3.
90. The method of claim 89, wherein the respiratory infection is caused by a virus or bacteria.
91. The method of claim 89, wherein the virus is respiratory syncytial virus, parainfluenza virus or human metapneumovirus.

XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

75. The IL-9 antibody of claim 71, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
76. The IL-9 antibody of claim 72, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
77. The IL-9 antibody of claim 74, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
78. The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
79. The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
80. The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
81. The IL-9 antibody of claim 78, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
82. The IL-9 antibody of claim 78, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-

92. The method of claim 89, wherein the inflammatory disorder is asthma, an allergy, arthritis or a disorder characterized by type 2-mediated inflammation.
93. The method of claim 89, wherein the autoimmune disorder is rheumatoid arthritis or multiple sclerosis.
94. The method of claim 89 further comprising a dosage of a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic agents other than an IL-9 antibody.
95. The method of claim 94, wherein at least one of the prophylactic or therapeutic agents is an anti-angiogenic agent, a TNF- α antagonist, an immunomodulatory agent, or an anti-inflammatory agent.
96. The method of claim 95, wherein the anti-angiogenic agent is VITAXIN™.
97. The method of claim 95, wherein the immunomodulatory agent is MEDI-507 or an anti-Epha2 antibody.
98. The method of claim 89, wherein the IL-9 antibody is administered parenterally, intranasally or orally.
99. The method of claim 89, wherein the subject is refractory to conventional therapies for the disease or disorder.
100. A method of diagnosing, prognosing, or monitoring a disorder or disease characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R comprising:
 - (a) assaying the level of IL-9 in cells or a tissue sample of a subject using the IL-9 antibody claim of 1, 2 or 3; and
 - (b) comparing the assayed level of IL-9 with a control level, whereby an increase or decrease in the assayed level of IL-9 compared to the control level of IL-9 is indicative of said disorder or disease.
101. A kit comprising the antibody of claim 1, 2 or 3 and instructions for use, in one or more containers.
102. An article of manufacture comprising a packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent

comprises the IL-9 antibody of claim 1, 2 or 3 and a pharmaceutically acceptable carrier.

103. An IL-9 antibody, wherein said IL-9 antibody has an association rate constant or k_{on} rate of at least $10^5 \text{ M}^{-1} \text{ s}^{-1}$.
104. The IL-9 antibody of claim 103, wherein said association rate constant or k_{on} rate is at most $10^{11} \text{ M}^{-1} \text{ s}^{-1}$.
105. An IL-9 antibody, wherein said IL-9 antibody has a dissociation rate constant or k_{off} rate of less than about $2 \times 10^{-4} \text{ s}^{-1}$.
106. The IL-9 antibody of claim 105, wherein said dissociation rate constant or k_{off} is greater than 10^{-11} s^{-1} .
107. An IL-9 antibody, wherein said IL-9 antibody has an affinity constant (K_a) of at least 10^7 M^{-1} .
108. The antibody of claim 107, wherein said affinity constant is at most $5 \times 10^{11} \text{ M}^{-1}$.
109. An IL-9 antibody, wherein said IL-9 antibody has dissociation constant (K_d) of less than 10^{-9} M .
110. The antibody of claim 109, wherein said dissociation constant is greater than $6 \times 10^{-12} \text{ M}$.